Tauvid™: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer's disease
Tauvid has been approved by the US Food and Drug Administration (FDA) in 2020 for
positron emission tomography (PET) imaging of adult patients with cognitive impairments …
positron emission tomography (PET) imaging of adult patients with cognitive impairments …
Sex differences in dementia with Lewy bodies: focused review of available evidence and future directions
SY Chiu, KA Wyman-Chick, TJ Ferman… - Parkinsonism & related …, 2023 - Elsevier
In this review, we summarize the current knowledge on sex differences in dementia with
Lewy bodies (DLB) relating to epidemiology, clinical features, neuropathology, biomarkers …
Lewy bodies (DLB) relating to epidemiology, clinical features, neuropathology, biomarkers …
Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and …
Y Hirschberg, N Valle‐Tamayo… - Journal of …, 2023 - Wiley Online Library
Dementia is a leading cause of death worldwide, with increasing prevalence as global life
expectancy increases. The most common neurodegenerative disorders are Alzheimer's …
expectancy increases. The most common neurodegenerative disorders are Alzheimer's …
Insights into the use of biomarkers in clinical trials in Alzheimer's disease
Biomarkers have been instrumental in population selection and disease monitoring in
clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of …
clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of …
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Dementia with Lewy bodies (DLB) is clinically defined by the presence of visual
hallucinations, fluctuations, rapid eye movement (REM) sleep behavioral disorder, and …
hallucinations, fluctuations, rapid eye movement (REM) sleep behavioral disorder, and …
[HTML][HTML] Fluid and biopsy based biomarkers in Parkinson's disease
DG Coughlin, DJ Irwin - Neurotherapeutics, 2023 - Elsevier
Several advances in fluid and tissue-based biomarkers for use in Parkinson's disease (PD)
and other synucleinopathies have been made in the last several years. While work …
and other synucleinopathies have been made in the last several years. While work …
Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies
BackgroundBlood biomarkers of Alzheimer's disease (AD) may allow for the early detection
of AD pathology in mild cognitive impairment (MCI) due to AD (MCI-AD) and as a co …
of AD pathology in mild cognitive impairment (MCI) due to AD (MCI-AD) and as a co …
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …
[HTML][HTML] Recent advances in Lewy body dementia: A comprehensive review
Abstract Lewy Body Dementia is the second most frequent neurodegenerative illness
proven to cause dementia, after Alzheimer's disease (AD). It is believed to be vastly …
proven to cause dementia, after Alzheimer's disease (AD). It is believed to be vastly …
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …